Popular Articles
-
Organizations in the News
(56 articles) Thoraxcenter at Erasmus University Medical Center
(39 articles) Massachusetts General Hospital
(38 articles) Harvard University
(28 articles) Wakayama Medical University
(22 articles) Case Western Reserve University
(21 articles) Royal Brompton Hospital
(19 articles) Cardiovascular Research Foundation
(17 articles) Nippon Medical School
-
Volcano Announces Activities at the ACC 2010
Explore Article ptca.org (Mar 12 2010) Cardiology , Other Business News
March 11, 2010 -- San Diego -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today its participation in the Annual Scientific Sessions of the American College of Cardiology (ACC) Conference from March 14th to March 16th in Atlanta, GA. "The Percutaneous Coronary Intervention (PCI) procedures that benefit from our technology are very complex, often involving multi-vessel disease, bifurcations, left mains, chronic total occlusions, intermediate lesions, or various combinations," commented Joe Burnett, Executive Vice President at Volcano. "Our message, ...Comment on Article Mentions: GE Healthcare Siemens Volcano
-
Volcano Expands Access to FFR with Ability to Integrate with the Majority of Hemodynamic Monitoring Systems
Explore Article PR Newswire (Mar 12 2010) Cardiology , Other Business News
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today its Fractional Flow Reserve (FFR) technology can now integrate with the FFR modules of hemodynamic monitoring systems from GE, Siemens, McKesson, and Mennen. "Utilization of Volcano's physiology (functional measurement) products has grown 79% in the last year, driven primarily by the landmark FAME data and recent elevation of the level of evidence for FFR in the ACC/AHA/SCAI PCI Guidelines to Level A," commented Scott ...Comment on Article Mentions: GE Healthcare Siemens Volcano
-
Swings and roundabouts: Intravascular Optical Coherence Tomography (OCT) in the evaluation of the left main stem coronary artery
Explore Article International Journal of Cardiology (Mar 11 2010) Cardiology
The imaging detail provided by Intravascular Ultrasound (IVUS) has contributed to 2 recent advances in the treatment of atherosclerotic left main stem coronary artery disease. First, the imaging of stent strut expansion has contributed to an increasing acceptance of left main stem stenting as an alternative to surgery , and second, precise measurements of the plaque area and residual lumenal area have allowed for improved quantification of left main lesion severity .Comment on Article Mentions: University of Sydney
-
Noninvasive Detection of Vulnerable Plaques: Are We There Yet?
Explore Article JACC (Mar 10 2010) Cardiology
We read with great interest the study by Motoyama et al. (1) demonstrating that patients with low-attenuation and positively remodeled plaques—as detected by computed tomography angiography (CTA)—were more likely to suffer from acute coronary syndromes (ACS) during follow-up. A total of 10,037 coronary segments >2 mm in diameter were analyzed in 1,059 patients; after a follow-up >2 years, 15 of these patients suffered ACS. Adverse CTA features (remodelling and/or low attenuation) were powerful predictors of ACS development after adjustment (hazard ratio: 22.8). This study is provocative indeed, considering that, up to now, the diagnosis of vulnerable plaque (VP) (defined as ... -
Volcano Corporation 10-K SEC Filing
Explore Article sec.gov (Mar 9 2010) Cardiology , Other Business News
The court has ordered the damages trial to commence on March 22, 2010. The court requested that the parties propose an appropriate modification to the terms of the existing preliminary injunction, but no revised preliminary injunction has been entered by the court. We intend to appeal the jury verdict and are not in the position to estimate the possible loss attributable to this verdict. We may be a party to various claims in the normal course of business. Legal fees and other costs associated with such actions are expensed as incurred and were not material in any period reported. Additionally, ... -
Automatic lumen segmentation from intravascular OCT images
Explore Article SPIE Digital Library (Mar 9 2010) Cardiology
In the last decade intravascular optical coherence tomography has known a tremendous progress. Its high resolution (5- 10µm) allows coronary plaque characterization, vulnerable plaque assessment, and the guidance of intravascular interventions. However, one intravascular OCT sequence contains hundreds of frames, and their interpretation requires a lot of time and energy. Therefore, there is a strong need for automated segmentation algorithms to process this large amount of data. In this article, we present an automated algorithm to extract lumen contours from images obtained with intravascular Optical Coherence Tomography (OCT). Unlike existing methods, our algorithm requires no post- or preprocessing of the ...
Comment on Article Mentions: Ecole Polytechnique de Montréal Guy Lamouche National Research Council Canada
-
Volcano Corporation Secondary Offering of ~ 1.2M Shares Current Market Cap ~ $1.2B
Explore Article 24/7 Wall St. (Mar 9 2010) Cardiology , Other Business News
offering below. Comerica Incorporated (NYSE: CMA) is down 2% at $35.58 right after the open on 5.4 million shares. Average volume here is only 2.45 million shares. Comerica sold $800 million via 22,857,143 shares of common stock at $35.00 per share to repay the TARP. Its market cap is 5.4 billion and the 52-week range is $11.91 to $37.32. Susquehanna Bancshares, Inc. (NASDAQ: SUSQ) is also paying off the TARP… or is it the TRAP? The company announced last night that it was offering $300 million in common stock and $50 million in Cumulative Trust Preferred securities. Shares are down ...
Comment on Article Mentions: Volcano
-
Volcano Corporation Presentation at Roth Capital Partners Conference to be Webcast
Explore Article PR Newswire (Mar 9 2010) Cardiology , Other Business News
SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the 22nd Annual Roth OC Growth Stock Conference on Tuesday, March 16. The presentation by John Dahldorf, chief financial officer, will begin at 2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time). The presentation will be available through the conference website at http://www.wsw.com/webcast/roth23/volc/ and via the company's website at www.volcanocorp.com. Volcano Corporation (Nasdaq: VOLC) offers a broad ...Comment on Article Mentions: Volcano John Dahldorf
-
Catheter for conducting a procedure within a lumen, duct or organ of a living being
Explore Article PatFT » Page 1 of 1 (Mar 9 2010) Cardiology , Patents
In an embodiment, the invention provides a catheter suitable for use in performing a procedure within a vessel, lumen or organ of a living having a distal end which is steerable, such as upon the application of compression. The catheter may be of the over the wire type, or alternatively may be a rapid exchange catheter. The catheter may provide for a rotating element which may be used to open a clogged vessel, or alternatively to provide information about adjacent tissues, such as may be generated by imaging or guiding arrangements using tissue detection systems known in the art, e.g., ...
-
Morphologic characteristics of late stent malapposition after drug-eluting stents implantation by optical coherence tomography follow-up
Explore Article Chinese Medical Journal (Mar 8 2010) Cardiology
Background Late stent malapposition was frequently observed after DES implantation, which has been associated with the occurrence of late stent thrombosis due to poor neointimal coverage. This study was designed to evaluate the frequency of late stent malapposition at least 1 year after different DESs implantation by optical coherence tomography (OCT).Methods Angiographic and OCT examinations were given to 68 patients who had received total 126 various DESs implantation for at least 1 year to detect late stent malapposition. Malapposed strut distance (MSD), malapposed strut area (MSA), reference lumen area (RLA) and reference stent area (RSA) were checked with off-line OCT ...
Comment on Article Mentions: LightLab Imaging Lightlab ImageWire
-
Gene Deletion Screen for Cardiomyopathy in Adult Drosophila Identifies a New Notch Ligand
Explore Article Circulation Research (Mar 7 2010) Cardiology , Developmental Biology
Rationale: Drosophila has been recognized as a model to study human cardiac diseases. Objective: Despite these findings, and the wealth of tools that are available to the fly community, forward genetic screens for adult heart phenotypes have been rarely performed because of the difficulty in accurately measuring cardiac function in adult Drosophila. Methods and Results: Using optical coherence tomography to obtain real-time analysis of cardiac function in awake Drosophila, we performed a genomic deficiency screen in adult flies. Based on multiple complementary approaches, we identified CG31665 as a novel gene causing dilated cardiomyopathy. CG31665, which we name weary (wry), has ...
Comment on Article Mentions: Duke University Bioptigen
-
Stentys self-expanding stent receives CE Marking to treat acute coronary syndrome (ACS)
Explore Article pcronline.com (Mar 5 2010) Cardiology , Other Business News
PRINCETON, N.J., and PARIS, March 5, 2010-Medical device pioneer Stentys announced today that it has received CE Marking for its self-expanding and disconnectable stent to treat acute coronary syndrome (ACS). The self-expanding feature of the Stentys platform, unrivaled in the stent industry, is designed to ensure optimal apposition of a stent in the critical initial hours and days after an acute myocardial infarction (AMI) procedure, by being continuously applied to the vessel's internal surface even during thrombus and vessel spasm relief-thereby avoiding malapposition, a significant concern to cardiologists. "For European regulatory approval we have demonstrated how the Stentys stent perfectly ... -
Australia & New Zealand Optical Coherence Tomography Workshop May 7th, 2010
Explore Article Optical Coherence Tomography News (Mar 5 2010) Cardiology
“Welcome to the Inaugural Australia & New Zealand Optical Coherence Tomography Workshop. We have set out a program with an internationally recognized faculty to review the use of OCT and discuss its exciting role in Interventional Cardiology. Thank you for joining us”. Peter Barlis & Rob Whitbourn. Enquiries to info@anzoct.org or go to www.anzoct.org. false false false EN-US X-NONE X-NONE
Comment on Article Mentions: Peter Barlis University of Melbourne LightLab Imaging
-
Volcano revenue rises, but bottom line shrinks
Explore Article sacbee.com (Mar 5 2010) Cardiology , Other Business News
San Diego-based medical equipment maker Volcano Corp., which operates a manufacturing facility in Rancho Cordova, saw sizable revenue gains in 2009 but posted losses for the final quarter and year. The company reported revenue of $71 million for the quarter ended Dec. 31, up 44 percent from $49.3 million in the year-ago period. The company said revenue was boosted by $5.8 million from Axsun Technologies Inc., which Volcano acquired in the fourth quarter of 2008. Still, Volcano lost $12.1 million, or 25 cents a share, in the final quarter, compared with earnings of $1.4 million, or 3 cents a share, ...Comment on Article Mentions: Axsun Technologies Volcano
-
Clinical studies of frequency domain optical coherence tomography in the coronary arteries: the first 200 patients
Explore Article SPIE Digital Library (Mar 4 2010) Cardiology
We report clinical study results of three-dimensional (3D) in vivo imaging of human coronary arteries using frequency domain optical coherence tomography (FD-OCT). At the time of this report, over 2000 patients in over 10 countries have been imaged using FD-OCT systems and disposable fiberoptic catheters developed by LightLab Imaging Inc. The first commercial versions of the systems were introduced in Europe in May 2009. The system operates at 50,000 axial lines/s, performing a 50 mm spiral pullback in 2.5 seconds with a rotational frame rate of 100 Hz. The commercial system employs a proprietary micro-cavity swept laser, allowing imaging of ...
Comment on Article Mentions: LightLab Imaging Desmond C. Adler Joseph M. Schmitt
RSS Feed
Recent Comments
Eric Swanson » Jim Fujimoto video: Biophotonics and optical coherence tomography
Great video Jim!
dariemihaela » Gary S. Mintz
Dear Prof. Dr. Gary S. Mintz, You are an extraordinary expert in imaging, an intelligence ...
See all recent comments